Abstract: A process for preparation of ceftiofur of formula (I) having purity greater than 97% is disclosed.

Abstract: A process for preparation of 7-[D-?-amino-?-(4-hydroxyphenyl)acetamido]-3-(1-propen-1-yl)-3-cephem-4-carboxylic acid viz. Cefprozil of formula (I) in high purity, substantially free of impurities, which comprises preparation of mixed acid anhydride by selecting the sequence and temperature of addition of the reagents and its subsequent condensation with a protected 7-APCA; followed by hydrolysis, isolation and purification to give Cefprozil of formula (I) in the form of a monohydrate.

Abstract: A process for preparation of ceftiofur of formula (I) of high purity and substantially free from impurities is disclosed.

Abstract: The present invention provides novel crystalline polymorphic forms and amorphous form of carvedilol dihydrogen phosphate characterized by different solid state techniques. The novel processes for their preparation are also disclosed.

Abstract: A process for preparation of ceftiofur sodium of formula (Ib) possessing high stability and having purity of more than 97% and substantially free of impurities, is disclosed. The process comprises: i) reacting cefotaxime or its salts or its esters of formula (VI) wherein R3 is hydrogen, an alkali or alkaline earth metal, or an easily hydrolysable ester, with thiofuroic acid, employed in a molar proportion of 1.5 to 3.0 moles per mole of compound (VI), in the presence of acetonitrile as solvent and in the presence of large excess of methanesulfonic acid, employed in molar proportions of 12 to 18 moles per mole of compound (VI), and at a temperature of between ?5° C. to 30° C.

Abstract: A process for preparation of 7-[D-?-amino-?-(4-hydroxyphenyl)acetamido]-3-(1-propen-1-yl)-3-cephem-4-carboxylic acid viz. Cefprozil of formula (I) in high purity, substantially free of impurities, which comprises preparation of mixed acid anhydride by selecting the sequence and temperature of addition of the reagents and its subsequent condensation with a protected 7-APCA; followed by hydrolysis, isolation and purification to give Cefprozil of formula (I) in the form of a monohydrate.

Abstract: The present invention relates to a simple and efficient process for the preparation of amorphous form of torsemide. The process includes recovering amorphous torsemide from a solution thereof in a suitable solvent comprising alcohols, ketones, chlorinated hydrocarbons, esters, nitriles, cyclic ethers, and mixtures thereof, by spray drying.

Abstract: A process for the preparation of highly pure crystalline form of cefuroxime-1-acetoxyethyl ester (cefuroxime axetil) from cefuroxime by reacting an amine salt of cefuroxime with an esterifying reagent.

Abstract: The present invention relates to a simple and efficient process for the preparation of amorphous form of torsemide, demonstrated in the X-ray diffraction pattern of FIG. 1.

Abstract: The present invention relates to a cost effective and industrially advantageous process for the preparation of amorphous cilastatin sodium.

Abstract: A process for preparation of ceftiofur sodium of formula (Ib) 1

Abstract: This invention relates to a novel amorphous form of sertraline hydrochloride and a process for the preparation thereof.

Abstract: A process for preparing cefuroxime axetil in substantially amorphous form comprises forming a mixture of crystalline cefuroxime axetil and at least one pharmaceutically acceptable excipient, and subjecting the mixture to milling for a period of time sufficient to convert the crystalline cefuroxime axetil to substantially amorphous form, i.e., the crystallinity is less than 5%. The amorphous cefuroxime axetil has a chemical purity of at least 95%. Desirably, the particles of the milled material are reduced to a size of less than 2.

Abstract: There is described a process for the preparation of a pure amorphous form of cefuroxime axetil which involves dissolving crystalline cefuroxime axetil in acetic acid including at least 5% v/v water and recovering said amorphous form of cefuroxime axetil from the solution by the addition of additional water, the solution being added all at once to the additional water being present in a volume which is sufficient to precipitate said amorphous cefuroxime axetil.

Abstract: A process for the preparation of highly pure crystalline form of cefuroxime-1-acetoxyethyl ester (cefuroxime axetil) from cefuroxime by reacting an amine salt of cefuroxime with an esterifying reagent.

Abstract: A process for preparing cefuroxime axetil in substantially amorphous form comprises forming a mixture of crystalline cefuroxime axetil and at least one pharmaceutically acceptable excipient, and subjecting the mixture to milling for a period of time sufficient to convert the crystalline cefuroxime axetil to substantially amorphous form, i.e., the crystallinity is less than 5%. The amorphous cefuroxime axetil has a chemical purity of at least 95%. Desirably, the particles of the milled material are reduced to a size of less than 2 .mu.m. The amorphous cefuroxime axetil prepared by this method may consist of R isomer, S isomer, or a racemic mixture of the R and S isomers.